The burgeoning landscape of innovative treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a https://saadvqhd742248.corpfinwiki.com/9470905/retatrutide_vs_tirzepatide_a_comparative_analysis